Compare Amgen, Inc. (AMGN) vs Extra Space Storage, Inc. (EXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Extra Space Storage, Inc. — how do they compare? Amgen, Inc. trades at $415.64 (market cap $224.14B), while Extra Space Storage, Inc. trades at $147.12 (market cap $30.96B). The key difference: Amgen, Inc. is far larger — about 7.2× Extra Space Storage, Inc.'s market cap, and Extra Space Storage, Inc. pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| AMGN | EXR | |
|---|---|---|
Market Cap | $224.14B | $30.96B |
Sector | Health | Real Estate |
52-Week High | $417.20 | $152.85 |
52-Week Low | $271.18 | $126.67 |
Enterprise Value | $267.45B | $44.68B |
Dividend Yield | 2.43% | 4.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $416.74, showing minimal daily movement with a slight 0.11% decline. The stock maintains strong technical momentum with bullish moving averages and support at $412. Fundamentally, the company demonstrates robust performance with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, while revenue growth continues with 2025 revenue reaching $36.75 billion. Analyst sentiment remains positive with 59% buy ratings, though the current price exceeds the consensus target of $394.69.
Amgen presents a mixed outlook with strong earnings momentum and product growth offset by valuation concerns. Investment opportunities include continued blockbuster drug performance and raised 2026 guidance, while risks involve high debt levels and potential data breach litigation impacts. The stock's current premium valuation requires sustained execution to justify further upside.
EXR trades at $147.22, up 0.38% today, near its 52-week high with a consensus price target of $157.25. The stock shows strong fundamentals, with Q2 2026 EPS beating estimates and a dividend yield supported by robust cash flow. Technicals are bearish on moving averages but neutral on oscillators, with key resistance at $148. Revenue growth has been steady, and the company maintains high profitability margins.
Outlook is positive with consistent earnings beats and a solid balance sheet, though high valuation multiples and competitive pressures pose risks. Analysts are mixed with a 'Hold' consensus, but institutional interest remains strong. The stock offers growth potential but requires monitoring of debt levels and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Extra Space Storage, Inc.
Extra Space Storage is a fully integrated real estate investment trust that owns, operates, and manages almost 2,100 self-storage properties in 41 states, with over 160 million net rentable square feet of storage space. Of these properties, approximately one half is wholly owned, while some facilities are owned through joint ventures and others are owned by third parties and managed by Extra Space Storage in exchange for a management fee.
Read more on EXR →
